University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655: pharmacodynamic and predictive potential in metastatic melanoma.

Ang, JE, Pal, A, Asad, YJ, Henley, AT, Valenti, M, Box, G, de haven Brandon, A, Revell, Victoria, Skene, Debra, Venturi, M, Rueger, R, Meresse, V, Eccles, SA, de Bono, JS, Kaye, SB, Workman, P, Banerji, U and Raynaud, FI (2017) Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655: pharmacodynamic and predictive potential in metastatic melanoma. Molecular Cancer Therapeutics.

[img] Text
Ang et al 2017 1535-7163.MCT-16-0881.full.pdf
Restricted to Repository staff only

Download (2MB)

Abstract

MAPK pathway activation is frequently observed in human malignancies, including melanoma, and is associated with sensitivity to MEK inhibition and changes in cellular metabolism. Using quantitative mass spectrometry-based metabolomics, we identified in preclinical models 21 plasma metabolites including amino acids, propionylcarnitine, phosphatidylcholines and sphingomyelins that were significantly altered in two B-RAF mutant melanoma xenografts and that were reversed following a single dose of the potent and selective MEK inhibitor RO4987655. Treatment of non-tumour bearing animals and mice bearing the PTEN null U87MG human glioblastoma xenograft elicited plasma changes only in amino acids and propionylcarnitine. In patients with advanced melanoma treated with RO4987655, on-treatment changes of amino acids were observed in patients with disease progression and not in responders. In contrast, changes in phosphatidylcholines and sphingomyelins were observed in responders. Furthermore, pre-treatment levels of 7 lipids identified in the preclinical screen were statistically significantly able to predict objective responses to RO4987655. The RO4987655 treatment-related changes were greater than baseline physiological variability in non-treated individuals. This study provides evidence of a translational exo-metabolomic plasma readout predictive of clinical efficacy together with pharmacodynamic utility following treatment with a signal transduction inhibitor.

Item Type: Article
Divisions : Faculty of Health and Medical Sciences > School of Biosciences and Medicine
Authors :
NameEmailORCID
Ang, JEUNSPECIFIEDUNSPECIFIED
Pal, AUNSPECIFIEDUNSPECIFIED
Asad, YJUNSPECIFIEDUNSPECIFIED
Henley, ATUNSPECIFIEDUNSPECIFIED
Valenti, MUNSPECIFIEDUNSPECIFIED
Box, GUNSPECIFIEDUNSPECIFIED
de haven Brandon, AUNSPECIFIEDUNSPECIFIED
Revell, VictoriaV.Revell@surrey.ac.ukUNSPECIFIED
Skene, DebraD.Skene@surrey.ac.ukUNSPECIFIED
Venturi, MUNSPECIFIEDUNSPECIFIED
Rueger, RUNSPECIFIEDUNSPECIFIED
Meresse, VUNSPECIFIEDUNSPECIFIED
Eccles, SAUNSPECIFIEDUNSPECIFIED
de Bono, JSUNSPECIFIEDUNSPECIFIED
Kaye, SBUNSPECIFIEDUNSPECIFIED
Workman, PUNSPECIFIEDUNSPECIFIED
Banerji, UUNSPECIFIEDUNSPECIFIED
Raynaud, FIUNSPECIFIEDUNSPECIFIED
Date : 22 June 2017
Identification Number : https://doi.org/10.1158/1535-7163.MCT-16-0881
Copyright Disclaimer : Copyright ©2017, American Association for Cancer Research. This is the author's accepted version.
Uncontrolled Keywords : metabolomics, MEK, pharmacodynamics, plasma biomarker, amino acids, phospholipids
Depositing User : Melanie Hughes
Date Deposited : 23 Jun 2017 08:34
Last Modified : 23 Jun 2017 08:34
URI: http://epubs.surrey.ac.uk/id/eprint/841474

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800